Ascendis Q3 product revenue reaches €366M as CHMP backs TransCon CNP in achondroplasia
Ascendis Pharma reported an operating profit of €125 million for Q3 2026 and a positive CHMP opinion for TransCon CNP, with an EU decision expected in Q4.
Ascendis Pharma reported third-quarter 2026 results on 12 November, with product revenue of €366 million. The company's headline title put the year-on-year increase at 89%. Operating profit for the quarter was €125 million.
YORVIPATH was the largest contributor at €291 million. SKYTROFA brought in €59 million and YUVIWEL €16 million.
On the regulatory side, the company noted positive opinions from the CHMP and the COMP for TransCon CNP in children with achondroplasia. The COMP is the EMA committee that reviews orphan designations, while the CHMP's opinion is the step that precedes a formal European Commission decision.
Ascendis expects the European Commission's final decision in the fourth quarter of 2026. It plans a first EU launch in Germany in the first quarter of 2027. The summary on file does not give further detail on the opinion, such as the approved indication wording or conditions.
Why it matters
- Regulatory teams tracking achondroplasia should watch for the European Commission decision, which Ascendis expects in Q4 2026.
- Market-access teams should note that Germany is the planned first EU launch market, targeted for Q1 2027.
- The combination of CHMP and COMP opinions signals progress on both marketing authorisation and orphan-status aspects of the TransCon CNP file.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
